DE69218241T2 - Arzneistofformulierung zur parenteralen anwendung - Google Patents
Arzneistofformulierung zur parenteralen anwendungInfo
- Publication number
- DE69218241T2 DE69218241T2 DE69218241T DE69218241T DE69218241T2 DE 69218241 T2 DE69218241 T2 DE 69218241T2 DE 69218241 T DE69218241 T DE 69218241T DE 69218241 T DE69218241 T DE 69218241T DE 69218241 T2 DE69218241 T2 DE 69218241T2
- Authority
- DE
- Germany
- Prior art keywords
- pct
- toremifene
- desmethyltamoxifen
- tamoxifen
- sec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919126209A GB9126209D0 (en) | 1991-12-10 | 1991-12-10 | Drug formulations for parenteral use |
| PCT/FI1992/000339 WO1993011757A1 (en) | 1991-12-10 | 1992-12-10 | Drug formulations for parenteral use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69218241D1 DE69218241D1 (de) | 1997-04-17 |
| DE69218241T2 true DE69218241T2 (de) | 1997-06-19 |
Family
ID=10706001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69218241T Expired - Fee Related DE69218241T2 (de) | 1991-12-10 | 1992-12-10 | Arzneistofformulierung zur parenteralen anwendung |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US5571534A (de) |
| EP (1) | EP0616529B1 (de) |
| JP (1) | JP3558344B2 (de) |
| AT (1) | ATE149828T1 (de) |
| AU (1) | AU667861B2 (de) |
| CA (1) | CA2125408C (de) |
| DE (1) | DE69218241T2 (de) |
| GB (1) | GB9126209D0 (de) |
| NO (1) | NO308578B1 (de) |
| WO (1) | WO1993011757A1 (de) |
| ZA (1) | ZA929592B (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2188612T3 (es) * | 1993-04-22 | 2003-07-01 | Skyepharma Inc | Liposomas multivesiculares de ciclodextrina para encapsular compuestos farmacologicos y metodos para su uso. |
| WO1995015746A1 (en) * | 1993-12-10 | 1995-06-15 | The School Of Pharmacy | Liposome delivery systems |
| GB9411115D0 (en) * | 1994-06-03 | 1994-07-27 | Secr Defence | Stabilisation of photosensitive material |
| GB9609171D0 (en) * | 1996-05-02 | 1996-07-03 | Orion Yhtymae Oy | Antioxidant compounds |
| ES2174388T3 (es) * | 1997-06-27 | 2002-11-01 | Akzo Nobel Nv | Solucion liquida de medicamento para administracion oral. |
| US6077871A (en) * | 1997-11-26 | 2000-06-20 | Pfizer Inc. | Droloxifene pharmaceutical compositions |
| AU761435B2 (en) | 1998-05-07 | 2003-06-05 | University Of Tennessee Research Corporation, The | A method for chemoprevention of prostate cancer |
| US20030130316A1 (en) * | 2000-03-20 | 2003-07-10 | Steiner Mitchell S. | Method for chemoprevention of prostate cancer |
| US20040092602A1 (en) * | 1998-05-07 | 2004-05-13 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6413535B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6632447B1 (en) * | 1998-05-07 | 2003-10-14 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US20040186185A1 (en) * | 1998-05-07 | 2004-09-23 | Steiner Mitchell S. | Method for treatment and chemoprevention of prostate cancer |
| WO2000033917A1 (de) * | 1998-12-04 | 2000-06-15 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten |
| FI109332B (fi) | 1998-12-17 | 2002-07-15 | Orion Yhtymae Oyj | Toremifeenin liukoisia koostumuksia |
| FI982733A (fi) * | 1998-12-17 | 2000-06-18 | Orion Yhtymae Oyj | Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia |
| US20040029831A1 (en) * | 2000-05-31 | 2004-02-12 | Kava Pharmaceuticals, Inc. | Extracts of kava-kava |
| US6303157B1 (en) | 2000-05-31 | 2001-10-16 | Kava Pharmaceuticals, Inc. | Extracts of kava-kava |
| US6899888B2 (en) | 2001-11-29 | 2005-05-31 | Otx, Inc. | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
| US20050239747A1 (en) * | 2004-04-21 | 2005-10-27 | Pharmaceutical Industry Technology And Development Center | Compositions and methods of enhanced transdermal delivery of steroid compounds and preparation methods |
| WO2006001035A2 (en) * | 2004-06-28 | 2006-01-05 | Lifecare Innovations Pvt. Ltd. | Synergistic liposomal tamoxifen composition for topical application and method of preparing thereof. |
| US20060019989A1 (en) * | 2004-07-21 | 2006-01-26 | Steiner Mitchell S | Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof |
| US20060116404A1 (en) * | 2004-09-24 | 2006-06-01 | Gary Robinson | CAI-based systems and methods for the localized treatment of ocular and other diseases |
| US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
| US20060105045A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Cyclodextrin solubilizers for liquid and semi-solid formulations |
| US20060105992A1 (en) * | 2004-11-08 | 2006-05-18 | Buchanan Charles M | Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds |
| WO2006066074A2 (en) | 2004-12-16 | 2006-06-22 | The Regents Of The University Of California | Lung-targeted drugs |
| US20060270641A1 (en) * | 2005-05-31 | 2006-11-30 | Steiner Mitchell S | Method for chemoprevention of prostate cancer |
| US20070014845A1 (en) * | 2005-07-01 | 2007-01-18 | Yuanpeng Zhang | Liposomal delivery vehicle for hydrophobic drugs |
| US8591457B2 (en) | 2005-08-10 | 2013-11-26 | Alza Corporation | Method for making a needle-free jet injection drug delivery device |
| WO2007078060A1 (en) * | 2005-12-30 | 2007-07-12 | Amorepacific Corporation | Polymer-liposome nano-complexes and the preparation method thereof, and the composition of skin external application containing the same |
| PT2076268E (pt) | 2006-10-19 | 2013-03-07 | Genzyme Corp | Roscovitina para o tratamento de certas doenças císticas |
| DK2415470T3 (en) | 2009-03-30 | 2016-09-19 | Eisai R&D Man Co Ltd | liposome |
| WO2010113983A1 (ja) * | 2009-03-30 | 2010-10-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | リポソーム組成物の製造方法 |
| EA201300341A1 (ru) | 2010-09-16 | 2013-09-30 | Шимода Байотек (Пти) Лтд. | Композиция фулвестранта и способы применения |
| WO2013008083A1 (en) | 2011-07-13 | 2013-01-17 | National Institute Of Pharmaceutical Education And Research (Niper) | Pharmaceutical composition for enhancing anticancer efficacy of tamoxifen |
| AU2012308453B2 (en) | 2011-09-18 | 2016-11-10 | Euro-Celtique S.A. | Pharmaceutical compositions |
| AR092790A1 (es) | 2012-02-01 | 2015-05-06 | Euro Celtique Sa | Derivados bencimidazolicos del acido hidroxamico |
| PL2970346T3 (pl) | 2013-03-15 | 2019-02-28 | The Regents Of The University Of California | Acykliczne diestry fosfonianowe nukleozydów |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| KR102589658B1 (ko) | 2014-09-15 | 2023-10-13 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 뉴클레오타이드 유사체 |
| CN105748442B (zh) * | 2016-04-07 | 2019-04-12 | 天津中医药大学 | 一种红景天苷及他莫昔芬的双载药抗乳腺癌纳米制剂的制备方法 |
| KR102543015B1 (ko) | 2016-06-17 | 2023-06-13 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법 |
| US11266631B2 (en) | 2016-10-11 | 2022-03-08 | Purdue Pharmaceutical Products L.P. | Hodgkin lymphoma therapy |
| GB201709403D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| PT3644999T (pt) * | 2017-06-30 | 2023-03-10 | Celgene Corp | Composições e métodos de utilização de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida |
| WO2019118855A1 (en) * | 2017-12-14 | 2019-06-20 | The Trustees Of The University Of Pennsylvania | Compounds and compositions for prevention and/or treatment of cancer |
| US11083705B2 (en) | 2019-07-26 | 2021-08-10 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumor |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5793909A (en) * | 1980-12-03 | 1982-06-11 | Sankyo Co Ltd | Carcinostatic pharmaceutical having directivity to specific internal organ and its preparation |
| FR2502951B1 (fr) * | 1981-04-06 | 1985-12-06 | Sandoz Sa | Compositions pharmaceutiques topiques sous forme d'une micro-emulsion |
| FI67538C (fi) * | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
| DE3331459A1 (de) * | 1982-08-31 | 1984-03-01 | Martin Dr.med. 6900 Heidelberg Berger | Zubereitung zur tumorbehandlung mit einem gehalt an diazoxid und dessen verwendung |
| EP0152379A3 (de) * | 1984-02-15 | 1986-10-29 | Ciba-Geigy Ag | Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen |
| JPS60208910A (ja) * | 1984-03-31 | 1985-10-21 | Green Cross Corp:The | 水難溶性薬物・リン脂質複合体の製造方法 |
| GB8604528D0 (en) * | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
| IE62095B1 (en) * | 1988-03-29 | 1994-12-14 | Univ Florida | Pharmaceutical formulations for parenteral use |
| JP2847783B2 (ja) * | 1988-08-11 | 1999-01-20 | 日清製粉株式会社 | 抗癌活性増強剤 |
| DE3827974A1 (de) * | 1988-08-18 | 1990-02-22 | Boehringer Mannheim Gmbh | Kombinationspraeparate von proteinkinase-c-inhibitoren mit lipiden, lipid-analoga, cytostatica oder inhibitoren von phospholipasen |
| MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
| DE3837596A1 (de) * | 1988-11-05 | 1990-05-10 | Rosink Gmbh & Co Kg | Kannenstock |
| FR2640137A1 (fr) * | 1988-12-08 | 1990-06-15 | Texinfine Sa | Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention |
| AU7963691A (en) * | 1990-05-17 | 1991-12-10 | Baylor College Of Medicine | Growth inhibitors and methods of treating cancer and cell proliferative diseases |
-
1991
- 1991-12-10 GB GB919126209A patent/GB9126209D0/en active Pending
-
1992
- 1992-12-10 EP EP93900114A patent/EP0616529B1/de not_active Expired - Lifetime
- 1992-12-10 AT AT93900114T patent/ATE149828T1/de not_active IP Right Cessation
- 1992-12-10 AU AU31599/93A patent/AU667861B2/en not_active Ceased
- 1992-12-10 US US08/244,549 patent/US5571534A/en not_active Expired - Lifetime
- 1992-12-10 WO PCT/FI1992/000339 patent/WO1993011757A1/en active IP Right Grant
- 1992-12-10 CA CA002125408A patent/CA2125408C/en not_active Expired - Lifetime
- 1992-12-10 DE DE69218241T patent/DE69218241T2/de not_active Expired - Fee Related
- 1992-12-10 JP JP51065093A patent/JP3558344B2/ja not_active Expired - Lifetime
- 1992-12-10 ZA ZA929592A patent/ZA929592B/xx unknown
-
1994
- 1994-06-09 NO NO942155A patent/NO308578B1/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3558344B2 (ja) | 2004-08-25 |
| AU3159993A (en) | 1993-07-19 |
| EP0616529B1 (de) | 1997-03-12 |
| NO942155L (de) | 1994-06-10 |
| ZA929592B (en) | 1993-08-06 |
| ATE149828T1 (de) | 1997-03-15 |
| US5571534A (en) | 1996-11-05 |
| CA2125408C (en) | 2004-04-20 |
| AU667861B2 (en) | 1996-04-18 |
| DE69218241D1 (de) | 1997-04-17 |
| NO308578B1 (no) | 2000-10-02 |
| JPH07501813A (ja) | 1995-02-23 |
| WO1993011757A1 (en) | 1993-06-24 |
| CA2125408A1 (en) | 1993-06-23 |
| GB9126209D0 (en) | 1992-02-12 |
| EP0616529A1 (de) | 1994-09-28 |
| NO942155D0 (no) | 1994-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69218241D1 (de) | Arzneistofformulierung zur parenteralen anwendung | |
| ES2569949T3 (es) | Formulaciones farmacéuticas que comprenden un péptido complejado con una dicetopiperazina | |
| ES2091012T3 (es) | Preparacion y utilizacion de nuevos sistemas coloidales dispersables a base de ciclodextrina, en forma de nanoesferas. | |
| ES2115945T3 (es) | Preparaciones topicas cosmeticas y medicinales. | |
| DE69305328T2 (de) | Mikrokapseln mit wänden aus primären alkoholfunktionen enthaltenden polysacchariden, und zusammensetzungen daraus | |
| DK0695171T3 (da) | Lyosfærer indeholdende gonadotropin | |
| PT790824E (pt) | Acidos carboxilicos 2,2-dicloroalcanos medicamentos contendo os mesmos e o seu uso para o tratamento da resistencia a insulina | |
| KR960000247A (ko) | 사이클로스포린a 함유 조성물 및 그의 제조방법 | |
| MXPA97007996A (es) | Preparado para el transporte de sustancias activas a traves de barreras. | |
| ES2090712T3 (es) | Medicamento agudo que contiene ibuprofeno y su uso. | |
| DK0945136T3 (da) | Topisk lægemiddel indeholdende ciclosporin | |
| DK0615443T3 (da) | Lægemiddel i akut virksom form indeholdende Flurbiprofen og anvendelse deraf | |
| DE69808938D1 (de) | Verfahren zur herstellung von pharmazeutischen zusammensetzungen | |
| JP2001278788A (ja) | アラントインを配合した安定な液剤 | |
| SE9103110D0 (sv) | New drug formulation | |
| KR980002033A (ko) | 트리아졸 유도체 또는 그 염 | |
| JPS57146723A (en) | Pharmaceutical preparation having improved absorption | |
| KR900701262A (ko) | 췌장염 등에 대한 치료제 | |
| DE69319589T2 (de) | Juckreizstillendes mittel | |
| DE69623641T2 (de) | Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen | |
| CA2456970A1 (en) | Drug formulations for parenteral use | |
| KR900016156A (ko) | 퀴녹살린 유도체 및 궤양치료제 | |
| KR900017599A (ko) | 종양 치료용 약학 조성물 | |
| US2611731A (en) | Antibiotic preparations | |
| RU95105249A (ru) | Гидрохлорид ng монометил-l-аргинина, способы его получения, способ получения фармацевтического препарата и способ лечения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: ORION CORP., ESPOO, FI |
|
| 8339 | Ceased/non-payment of the annual fee |